Building an integrated biotechnology platform

Biotechnology has no shortage of promising science. The real challenge is turning that science into products that can be manufactured reliably, economically and at industrial scale.

At Mycofeast, we're building a platform that connects the capabilities needed to make this happen — from advanced strain and enzyme engineering through process development and scale-up to industrial manufacturing.

Our growing international operations bring together complementary strengths:

In California, Evolutia Bio provides advanced R&D capabilities, combining strain and enzyme engineering, high-throughput screening and computational biology to develop and optimise biological production systems.

In New Zealand, Daisy Lab brings expertise in precision fermentation, recombinant protein development, bioprocess optimisation and downstream processing, with a particular focus on high-value dairy proteins such as lactoferrin.

In Poland, we're transforming a former Heineken brewery into a biotechnology manufacturing facility, combining existing industrial infrastructure with new fermentation capabilities. This brownfield approach is central to our strategy of making industrial biotechnology more capital-efficient and commercially viable.

Together, these capabilities create a connected pathway from scientific discovery to commercial production.

Our applications span functional beverage ingredients, carotenoids, high-value proteins and other fermentation-derived bioactives. Different products, but a shared focus on developing solutions that make sense scientifically, economically and commercially.

We believe the future of industrial biotechnology will be shaped not only by what science can achieve, but by how effectively we can translate innovation into products that reach the market.

That's the platform we're building at Mycofeast.

Next
Next

FoodBev covers Mycofeast's acquisition of Daisy Lab